Safety and Tolerability of Stem Cell Transplant and Polatuzumab Vedotin Therapy for B-cell and Hodgkin Lymphoma Patients

What this Trial Is About

This trial studies patients with various types of B-cell non-Hodgkin lymphoma and Hodgkin lymphoma who receive autologous stem cell transplant ASCT after a conditioning regimen. The purpose is to evaluate the safety and tolerability of adding Polatuzumab Vedotin immunoconjugate therapy after ASCT. Patients must have specific lymphoma diagnoses and either stable or responding disease after prior therapies to participate. Participants first undergo one of two myeloablative conditioning treatments, BEAM or CBV, followed by ASCT on Day 0. Supportive care with sargarmostim and filgrastim is given until blood counts stabilize. If patients achieve complete, partial, or stable response after ASCT, they receive intravenous Polatuzumab Vedotin every 21 days for up to eight doses. After completing Polatuzumab Vedotin therapy, patients are monitored for about two years with follow-up visits every four months. During the study, researchers will monitor safety and tolerability for one year and assess event-free survival, progression-free survival, overall survival, and overall response rates for two years. Evaluations include performance status, organ function tests, and stem cell counts before ASCT. Safety assessments and response evaluations occur throughout treatment, and long-term follow-up monitors patient outcomes. Participation lasts several years including treatment and observation periods.

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma